Study on the effect of glycemic control on mean platelet volume in type 2 diabetic patients on treatment. by Doron Susan, Mathew
A Dissertation on 
STUDY ON THE EFFECT OF GLYCEMIC CONTROL ON 
MEAN PLATELET VOLUME IN TYPE 2 DIABETIC PATIENTS 
ON TREATMENT 
 
Submitted to 
 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI – 600032 
 
In partial fulfilment of the Regulations 
for the Award of the Degree of 
 
M.D. BRANCH - I 
 
GENERAL MEDICINE 
 
 
 
DEPARTMENT OF GENERAL MEDICINE 
STANLEY MEDICAL COLLEGE 
CHENNAI – 600 001 
 
APRIL 2015 
 CERTIFICATE BY THE INSTITUTION 
 
 
                This is to certify that Dr. DORON SUSAN MATHEW, Post - Graduate 
Student (May 2012 TO April 2015) in the Department of General Medicine 
STANLEY MEDICAL COLLEGE, Chennai- 600 001, has done this dissertation 
on “STUDY ON THE EFFECT OF GLYCEMIC CONTROL ON MEAN 
PLATELET VOLUME IN TYPE 2 DIABETIC PATIENTS ON 
TREATMENT”  under my guidance and supervision in partial fulfillment of the 
regulations laid down by the Tamilnadu Dr. M. G. R. Medical University, Chennai, 
for M.D. (General Medicine), Degree Examination to be held in April 2015. 
 
 
 
 
 
Dr. R.JAYANTHI, M.D. 
Professor and HOD 
Department of Medicine, 
Govt. Stanley Medical College & Hospital, 
 
  
 
 
Dr A. L. MEENAKSHI SUNDARAM, 
M.D, D.A. 
 The Dean 
Govt. Stanley Medical College &    Hospital, 
Chennai – 600001 
  
                              CERTIFICATE BY THE GUIDE 
 
 
 
                This is to certify that Dr.DORON SUSAN MATHEW, Post - Graduate 
Student (MAY 2012 TO APRIL 2015) in the Department of General Medicine 
STANLEY MEDICAL COLLEGE, Chennai- 600 001, has done this dissertation 
on “STUDY ON THE EFFECT OF GLYCEMIC CONTROL ON MEAN 
PLATELET VOLUME IN TYPE 2 DIABETIC PATIENTS ON 
TREATMENT”  under my guidance and supervision in partial fulfilment of the 
regulations laid down by the Tamilnadu Dr.M.G.R. Medical University, Chennai, 
for M.D. (General Medicine), Degree Examination to be held in April 2015. 
 
 
 
Dr. R.JAYANTHI, M.D. 
Professor and HOD 
Department of Medicine, 
Govt. Stanley Medical College & Hospital, 
 
  
        . 
 
                                      DECLARATION 
I, Dr. DORON SUSAN MATHEW, declare that I carried out  this  work  on 
“STUDY ON THE EFFECT OF GLYCEMIC CONTROL ON MEAN 
PLATELET VOLUME IN TYPE 2 DIABETIC PATIENTS ON 
TREATMENT” at the Diabetology OPD and Medical wards of Government Stanley 
Hospital during the period March 2014 to September 2014. I also declare that this 
bonafide work or a part of this work was not submitted by me or any other for any award, 
degree, or diploma to any other university, board either in India or abroad. 
This is submitted to The Tamilnadu DR. M. G. R. Medical University, Chennai in 
partial fulfilment of the rules and regulation for the M. D. Degree examination in General 
Medicine. 
 
 
Dr.DORON SUSAN MATHEW 
  
ACKNOWLEDGEMENT 
At the outset I thank our dean Dr.A.L. MEENAKSHI SUNDARAM M.D., 
D.A, for permitting me to carry out this study in our hospital. 
I express my profound thanks to my esteemed Professor and Teacher Dr. R. 
JAYANTHI, M.D.,Professor and HOD of General Medicine, Stanley Medical 
College Hospital, for encouraging and extending invaluable guidance to perform 
and complete this dissertation. 
I sincerely thank Dr. S Subhasree, Head, Dept. of Diabetology, Government 
Stanley Medical College for the guidance. 
I wish to thank Dr.C. S. GAUTHAMAN, Dr HEMA M, Assistant 
Professors of my unit Department of Medicine, Stanley Medical College Hospital 
for their valuable suggestions, encouragement and advice. 
I sincerely thank the members of Institutional Ethical Committee, Stanley 
Medical College for approving my dissertation topic. 
I thank all my colleagues, House Surgeons, and Staff nurses and other para 
medical workers for their support. 
Last but not the least; I sincerely thank all those patients who participated in 
this study, for their co-operation. 
ABBREVIATIONS 
T3 : T3-Triiodothyronine 
T4 : T4-Thyroxine 
TSH : Thyroid Stimulating Hormone 
HbA1c : Glycosylated Haemoglobin 
FPG : 
Fasting Plasma Glucose 
 
PPBG : Post Prandial Blood Glucose 
MPHA : Megakaryote- platelet hemostatic axis 
LDL : Low Density Lipoproteins 
TGL : Triglycerides 
HDL : High density lipoproteins 
MPV : Mean platelet volume 
IDF : International diabetes federation 
ADA : American Diabetes Assocation 
OHA : Oral hypoglycemic agents 
SEAR :    South East Asian Region 
GDM        :       Gestational Diabetes Mellitus  
ICMR  :      Indian Council of Medical Research 
LADA :  Latent Autoimmune Diabetes in adults 
GAD          :   Glutamic acid decarboxylase 
MODY      :    Maturity onset diabetes of young 
DCCT         :   Diabetes control and complication trial 
NGSP  :   Nationalised glycolhemoglobin standardisation  
  programme 
OGTT   :   Oral glucose tolerance test 
UKPDS   :   United Kingdom prospective diabetes study 
ADP :  Adenosine Diphosphate 
BMI :  Body mass index 
2,3 DPG    :    2,3 Diphosphoglycerate 
RBC :    Red blood cell 
vWF :     von Willebrand Factor 
PDW     :    Platelet distribution width 
PCT :   Plateletcrit 
PLCR      :   Platelet large cell ratio 
LDH :    Lactate dehydrogenase 
Tx  A2 :     Thromboxane A2 
NO :     Nitric oxide 
PDEGF :  Platelet derived epidermal growth factor 
IGF    1 :   Insulin like growth factor 1 
PF4      :      Platelet factor 4 
PAI  :     Plasminogen activator inhibitor 
 
 
 
 
 
CONTENTS 
S. NO.                               TITLE                                                PAGE  NO. 
1.  INTRODUCTION  1 
2. AIM OF STUDY 3 
3. REVIEW OF LITERATURE 4 
4. MATERIALS AND METHODS 57 
5. RESULTS 62 
6. DISCUSSION  104 
7. CONCLUSION 110  
 
                       ANNEXURES 
a) BIBLIOGRAPHY 
b) PROFORMA 
c) MASTER CHART 
d) KEYS TO MASTER CHART 
e) ABBREVIATIONS 
 
 
ABSTRACT 
Introduction 
Diabetes mellitus is a global pandemic. The increased platelet activity may play a 
role in the development of vascular complications of this metabolic disorder. The 
mean platelet volume (MPV) is an indicator of the average size and activity of 
platelets. Larger platelets are younger and exhibit more activity. 
Increased mean platelet volume is a known risk factor for various acute vascular 
complications, which is commonly associated with patients with diabetes mellitus. 
This study was aimed to investigate the association of Mean Platelet Volume 
(MPV) with glycemic control in Type 2 Diabetes Mellitus (DM). 
Material and Methods 
 A total of 100 patients were selected and allocated to three Groups according to 
their HbA1C level. Investigations like fasting blood glucose, HbA1Cand MPV 
were performed. Relation of MPV was assessed with HbA1C and FBS, PPBS, 
duration of diabetes. To find the significance difference between the bivariate 
samples in independent groups the Independent sample t-test was used. For the 
multivariate analysis the one way ANOVA was used. In both the above statistical 
tools the probability value .05 is considered as significant level. 
 
Results  
The mean platelet counts and MPV were higher in diabetics with poor glycemic 
control defined as HbA1C more eight {[7.29+/-.786(<7)], [7.9+/-.659(7.1-8)] and 
[8.76+/-1.068(>8)fl]   than compared to the patients with good control. MPV 
showed a strong positive correlation with HbA1C levels (P=0.001). 
Conclusion 
This study has shown an elevation in Mean Platelet Volume in patients with 
increased HbA1C (glycated hemoglobin) values, thus indicating poor control of 
diabetes and, it can be stated that an increase in Mean Platelet Volume is directly 
proportional to the numerical value of HbA1C (glycated hemoglobin) and 
inversely related to the control of diabetes. Statistically significant association was 
found with glycated hemoglobin (HbA1C) (P-value =.0001) and mean platelet 
volume. 
Keywords: Diabetes mellitus, glycemic control,HbA1C(glycated hemoglobin), 
mean platelet volume 
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INTRODUCTION 
Diabetes mellitus is a rapidly increasing endocrinological 
disorder in both developed as well as developing nations. 
Diabetes mellitus is a disease of antiquity known to mankind 
since past 3500 years. Ancient Indian scholars like Charak and 
Sushrutha recorded about this in the past. It is a big concern because of 
the devastating effects of its complications. 
Mean Platelet Volume (MPV) is a new and independent risk 
factor for atherosclerosis. Studies have shown that increased MPV is a 
risk factor for transient ischemic attack, myocardial infarction, and 
cerebral ischemia1. Altered platelet morphology and function have 
been reported in patients with Diabetes Mellitus (DM) and MPV was 
found to be significantly higher in diabetic patients2,3, thereby playing 
role in the micro- and macro-vascular complications of diabetic 
patients. The prevalence of diabetic microvascular complications is 
more in people with poor glycemic control and longer duration of 
DM4. 
A large proportion of patients with Type 2 DM suffer from 
preventable vascular complications. There is a need to develop risk 
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factor modification interventions to reduce the impact of long term 
complications. Study by Kodiatte TA et al., showed that in diabetes 
mellitus, platelets become more reactive and their Mean 
Volume (MPV) is increased. The increased platelet size may be 
one factor in the increased risk of atherosclerosis associated with 
diabetes mellitus and associated vascular complications. Hence, MPV 
would be a useful prognostic marker of cardio-vascular complications 
in diabetes. 
Although the underlying mechanism of higher MPV in diabetic 
subjects is incompletely understood, but thought to be due to osmotic 
swelling as a result of hyperglycemia 5. Alternatively,increased platelet 
size may reflect the presence of high platelet turnover and younger 
platelets6. 
Study by Shah B et al., showed that mean platelet volume is 
strongly and independently associated with the presence and severity 
of diabetes. The association between MPV and diabetes was most 
apparent in those with the poorest glucose control7. 
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AIM OF THE STUDY 
To study the effect of glycemic control on mean platelet volume 
among Type II diabetic patients on treatment.                        
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REVIEW OF LITERATURE 
DIABETES 
Diabetes mellitus refers to a group of common metabolic 
disorders consisting of different subtypes of diabetes with 
hyperglycemia due to insulin deficiency, either absolute or relative as a 
common factor. Diabetes mellitus exist in several distinct forms and is 
caused by several complex interaction of environmental and genetic 
factors. The prevalence of diabetes mellitus has risen dramatically over 
the past few decades from an estimated thirty million cases in 1985 to 
177 million in 2000 to 382 million in 2013 according to the 
International diabetes federation 2013,diabetes atlas 6th edition.8 Based 
on current trends,>592 million individuals will have Diabetes by the 
year 2032. 
Diseases with cardinal features of diabetes mellitus were 
recognized in ancient times. Georg Ebers discovered an Egyptian 
papyrus from 1550 BC which described a polyuric state. The term 
diabetes was first used by Aretaeus from Cappadocia, from the word 
syphon which in Greek means the fluid does not remain in the body, 
but the man’s body is used as a channel. The Hindu physicians, Charak 
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and Sushrut,where probably the first to recognize the sweetness of 
diabetic urine which was recorded between 400 and 500 BC. 
The first description of hyperglycemia was published in 1776 in 
a paper by Matthew Dobson of Liverpool9. In 1815 the sugar in 
diabetic urine was proved to be glucose or grape sugar by the French 
chemist Michel Chevreul10. Between 1846 and 1848 a French 
physiologist, Claude Bernard hypothesized the glycogenic theory thus 
clarifying the glucose metabolism 11 in 1869 Paul Langerhans 
discovered and described an island of cells from pancreatic tissue and 
in 1893 ,Gustave Laguesse suggested internal secretions from the 
island of cells isolated from the pancreas and named them islets of 
Langerhans 12,13. In 1909 the glucose lowering internal secretion of the 
islets was named by the Belgian jean de Meyer as insulin[Latin island]. 
The term insulin was given by Macleod unaware of de Meyer’s earlier 
suggestion of insuline14 
Banting and best where the first to discover insulin as a 
therapeutic agent, in 1922 the first clinical trial of insulin was done 
with an extract made by Best. Frederick Sanger reported the amino 
acid sequence of insulin in 195515. Dorothy Hodgkin in 1969 the three 
dimensional structure of insulin16. Wang Ying-lai and his colleagues  
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In Shanghai synthesized complete insulin molecule from amino acids 
in 196517. 
EPIDEMIOLOGY 
The prevalence of diabetes has increased by leaps and bounds in 
India and has reached epidemic proportions. India has more than 62 
million diabetic patients. Thus it is vital to epidemiological data on 
diabetes from all over the world. According to international diabetes 
federation 2013 in china has the largest population of diabetics of 
about 98.4 million, India being second with 65.1 million and USA 24.4 
million diabetics. IDF 2013 also gives the data of total diabetics in the 
world to be around 382 million which is estimated to rise by around 
55% to reach 592 million diabetic population by the year 2032. The 
study also gives the data of SEAR countries to inhabit 72.1 million of 
diabetic population in 2013 which is postulated to increase to 123 
million by 2032 that is a 71% rise from the present diabetic 
population.18 
Definitive data from population based studies on prevalence of 
type 1 diabetes is not available from India. However, it is relatively 
rare in our country and less than 2% of the diabetics in India are having 
type 1 diabetes. Asian continent has lowest incidence rate of type1 
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diabetes, approximately 0.5cases per annum per lakh population. 
However recently it has been postulated that some patients who have 
onset of diabetes in the middle age and whose symptoms develop 
gradually and who develop either primary failure or early secondary 
failure to sulfonylureas, are actually suffering from late onset and 
slowly progressing subtype of type 1 diabetes. Immunological markers 
for type 1 diabetes are positive in these patients. There are few studies 
on these patients from south India, but epidemiological studies are 
lacking. 
Prevalence of type 1 diabetes increases as one travels from 
southern to northern hemisphere. About 15-20% of diabetics in 
northern European countries are having type 1 diabetes. Among the 
countries in the European continent, there are significant north south 
difference as regards incidence. Incidence rate of type 1 diabetes in 
Finland28 per 1 lakh as against 6 per 1 lakh in France. In addition to 
geographical variation there is a seasonal variation in the incidence 
rate. More cases are diagnosed in winter. This is attributed to seasonal 
variation for viral infection which trigger autoimmune destruction of 
beta cells in pancreas leading toacute onset diabetes. An interesting 
finding about incidence is that in USA, incidence is much higherin 
white population as compared to blacks in the same area. Since the 
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environmental factors are same for both the ethnic groups, the 
difference in incidence isprobably based on genetic factors. Offspring 
oftype 1 diabetic father are 3 times more likely to develop it by the age 
of 20 years as compared to that of type 1 diabetic mother (6%vs2%). It 
is postulated that exposure to diabetic environment in utero offers 
protection, perhaps by inducing immunological tolerance to the antigen 
involved in autoimmune destruction of pancreatic beta cells. However 
genetic factors are less important in pathogenesis of type 1 diabetes as 
compared to type 2 diabetes. This has been amply true by the studies 
done in twins. 
Relationship between type1 diabetes occurrence and certain 
HLA antigens: in the early seventies, certain HLA antigens were 
shown to be positively associated with type 1 diabetes but not with 
type 2 diabetes. Although initially certain HLA B antigens were 
identified for association with type 1 diabetes, DR antigens have    
since been shown to have stronger association with the disease. In all 
the population studied, type 1 diabetes has been confined largely to the 
individuals who carry HLA DR 3 or HLADR4 antigen. 
As against incidence studies in type 1 diabetes, prevalence 
studies are more commonly done in type 2diabetes. It has become 
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epidemic in many developing and rapidly industrializing countries 
including India. In our country more than 96% of diabetics have type 2 
diabetes. Prevalence of type 2 diabetes which wasabout2% in early 70s 
has sharply risen to more than 8% in late 90s and more than 14% in 
recent surveys in urban areas of our country. As per the latest 
prevalence study done by ICMR in 2011, India has 62.4 million 
diabetics and 72.2 million prediabetes. 
Prevalence rate of type2 diabetes correlate with the degree of 
modernization and many societies which are rapidly undergoing a 
transformation from traditional to modern lifestyle are experiencing 
some of the highest rate of diabetes. Over the years, epidemiological 
studies done indifferent parts of the globe has shown that the Indian 
migrants settled abroad has a higher prevalence as compared to the 
local host population living in identical environment as well as the 
population native in India. This has been reported from countries with 
long established Indian population such as Singapore, Fiji islands, 
South Africa, Tanzania, Uganda, Trinidad and UK. Data generated 
over last two decades from our country have proved that the prevalence 
of type2 diabetes rapidly rising among urban population and is 
approaching the prevalence rates seen in the migrant Indian population. 
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While there is a drastic increase in prevalence rate in urban India, the 
prevalence in rural India has increased at slower rate. Consumption of 
traditional diet and relative absence of mechanization have protected 
the rural population. However as per recent survey done in Tamilnadu, 
prevalence of diabetes is rapidly rising even in rural areas. In PODIS 
study by Mohan and his group, prevalence of type 2 diabetes was 
4.26% in rural areas. Another very worrisome finding is reduction in 
prevalence rate of impaired glucose tolerance (prediabetes). It means 
faster conversion of these people to diabetes and thus more rapid rise 
in prevalence of diabetes. 
However as per recent study done by ICMR in 2011, in the 
states of Tamilnadu, Maharashtra, Jharkhand and in the city of 
Chandigarh, India already has 62.4 million people with diabetes, thus 
we are likely to surpass the figure of 79.4million much before the year 
of 2030. 
There is a large variation in prevalence of type 2 diabetes 
between the communities. The highest rates are found in some native 
American tribes such as Pima Indians (over 50%),while low 
prevalence rates are found in least developed rural communities in 
many Afro-Asian countries(3%). 
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Gestational diabetes occurs in about 4% of pregnancies in the western 
world. In a study done in Chennai in 2003 the prevalence of GDM was 
10.7% in rural and16.7% in urban areas. In the majority of cases, blood 
glucose returns to normal in postpartum period but the life time risk for 
future diabetes is substantially increased in women who develop GDM. 
About 40% develop diabetes in next 10 years. 
The epidemics of interrelated lifestyle disorders have struck the 
globe like tsunami with its epicenter in rapidly developing and 
industrializing Asian continental India and China. A global epidemic 
of type 2 diabetes is occurring, particularly affecting developing 
countries and migrant population from these countries to more 
industrialized and westernized societies. This epidemic has closely 
followed the epidemic of obesity. The epidemic of type 2 diabetes 
itself is being closely followed by that of cardiovascular disorders 
particularly coronary artery disease. Until recently, based on the 
available epidemiological data, which was outdated to some extent, it 
was believed that India has a dubious distinction of having more 
diabetic patients than any other country including China. However, 
India is probably not the country with highest number of diabetics 
anymore. Recently(March 2010) a large scale epidemiological survey 
was done across China to study the prevalence of diabetes in that 
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country. Instead of using fasting plasma glucose as the sole test as done 
in early epidemiological studies, the survey also did post 75g glucose 
blood glucose levels in all the people who were included in the survey. 
It was found out that there are about93 million diabetic patients in 
China. Based on the earlier surveys it was estimated that china has 
about 39 million diabetic people, a figure lower than the estimated 
figure for prevalence of diabetics in India. However with 2011 data 
from ICMR study, we now know that the difference between the 
Chinese diabetic population based on the recent data and the Indian 
diabetic population is smaller. 
As estimation of post glucose load blood glucose level is 
cumbersome and time consuming,  Most of the epidemiological studies 
use fasting plasma glucose which is a bit less sensitive as compared to 
post 75 g glucose load plasma glucose level. However if a scientific 
national survey is done in our country using same methods of diagnosis 
of diabetes as used in the recent study in China, the prevalence of 
diabetes is likely to be much higher. 
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CLASSIFICATION 
Diabetes mellitus fall into two major etiopathogenic category 
type 1 and type two diabetes. Diabetes can also develop secondary to 
other causes like genetic defects in beta cell functions, genetic defects 
in insulin action, diseases of exocrine pancreas or intake of certain 
drugs. 
Onset of type 1 diabetes is usually in childhood and very acute. 
The patients with insulin dependent diabetes mellitus depend on insulin 
for their survival and withdrawal of insulin lead to ketoacidosis. 
Autoimmune or idiopathic destruction of insulin producing beta cells 
in Istets of Langerhans result in decreased endogenous insulin 
production vital for glycemic control and other metabolic function. 
Initial presentation of type 1 diabetes is usually dramatic with severe 
symptoms of polyuria, polydipsia, polyphagia,weightloss and in some 
cases diabetic ketoacidosis with symptoms of vomiting, deep rapid 
breathing characteristic of acidosis and deteriorating level of 
consciousness. Type 1 diabetes usually present in childhood and in 
young adults. Occasionally middle age people present with type 1 
diabetes in some middle aged patients first presentation of type 1 
diabetes is similar to type 2 which is more common in this age group.  
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In the early stages the may show response to oral hypoglycemic agents 
and are labelled wrongly as type 2 patients. However they become 
insulin dependent over a shorter period when compared to an average 
type 2 diabetic patient. These patients are positive for GAD antibodies 
confirming type 1 diabetes. These patients are labeled LADA[latent 
autoimmune diabetes in adults]. 
Type 2 diabetes the most common type all over the world, was 
labeled non-insulin dependent diabetes in the nineties. In type 2 
diabetes environmental and genetic factors interplay leading to a chain 
of events  ultimately leading to diabetes .most patients have varying 
degrees of dual defects, beta cell dysfunction and insulin resistance . 
Acquired insulin resistance can be multifactorial. Stress, drugs, 
sedentary life style are a few of the factors leading to acquired insulin 
resistance. 
Secondary diabetes or other specific types of diabetes that are 
related to other specific disease process or genetic disorder19,20. 
Secondary diabetes represent includes a variety of condition because of 
a recognized underlying pathology, a well-defined hyperglycemia 
governing molecular defect and or a clear association of a well-defined 
clinical syndrome and diabetes. This category of secondary diabetes  
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consist of genetic disorders of beta cell function and the insulin action , 
inflammatory infiltrative and neoplastic diseases of pancreas, 
endocrinopathies  and infectious diseases leading to diabetes or certain 
medication and chemical exposure and rare forms of immune  
mediated diabetes  and a variety of congenital syndromes associated   
hyperglycemia. 
Maturity onset diabetes of the young [MODY] is a 
heterogeneous group of hyperglycemic disorder inherited in an 
autosomal dominant manner .MODY patients are usually not obese 
and only mildly hyperglycemic. Ketoacidosis is usually not seen the 
disorder is mild in nature and mask the clinical disorder for many 
years.  Typically the disease occurs before 25 of age in childhood or 
adolescents. A strong family history of diabetes in multiple generation 
is usually present. Primary defects in beta cell function is responsible 
for all cases of MODY. MODY is numbered one through six according 
to the six separate genetic mutation  
MODY 2 is characterized  by mutation in the gene encoding the 
glycolytic enzyme, glucokinase. In  MODY 1  hepatocyte nuclear  
factor 4 alpha , in MODY 3 hepatocyte nuclear  factor 1 alpha , in 
MODY 4 insulin promoter factor 1,in MODY 5 hepatocyte nuclear 
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factor  1 beta and  in MODY 6 neurogenic  differentiation factor 1 are 
the transcription factors encoded by the genes affected by the genetic 
defect in MODY21. The most prevalent of the group is MODY 3 and 
the next common is MODY 2. 
Genetic defects in insulin action.  The insulin molecule or its 
receptor abnormality are rare condition that can lead to diabetes in 
infancy. Leprechaunism is characterized by severe insulin resistance, 
intrauterine growth retardation, dysmorphic features and acanthosis 
nigricans. Type A insulin resistance with acanthosis nigricans, 
lipodystrophic diabetes, Rabson Mendenhall syndrome 
(dentaldysplasia, dystrophic nails, precocious puberty) are the other 
forms of diabetes in under the category of genetic defects in insulin 
action. Peroxisome  proliferator activated receptor gamma is associated 
with severe insulin resistance and diabetes. 
Acute and chronic pancreatitis, hemochromatosis and cystic 
fibrosis can affect the parenchymal tissue of pancreas and can cause 
diabetes in later life. Malnutrition related fibrocalculous pancreatitis 
and carcinoma of pancreas is linked to diabetes  
A number of medication has been related to the development of 
diabetes. Drugs associated with insulin resistance include 
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glucocorticoids, levothyroxine, atypical antipsychotics. Beta 
adrenergic antagonist, thiazide diuretics, calcium channel blockers and 
octreotide are agents that decrease insulin secretion. Beta cell 
destruction may be caused by rodenticide, vacor. Viral agents like 
rubella, mumps, coxsackie and adenovirus may produce immune 
response leading to type 1 diabetes. Stiffman syndrome with high anti-
GAD antibody titers and diabetes is an autoimmune mediated 
condition. in congenital syndromes like Down’ s syndrome Klinfelter’s 
syndrome, Friedrich’s  ataxia ,Turner’s syndrome, Prader-Willi 
syndrome, myotonic dystrophy, Wolfram’ssyndrome, Porphyria, 
Laurence Moon Beidl syndrome, diabetes is recorded with increased 
frequency.  
Diabetes first diagnosed during pregnancy is termed gestational 
diabetes. It occurs in about 2 to 5 % of all pregnancies. Gestational 
diabetes results from insulin resistance of pregnancy interacting with 
beta cell defect. Usually blood glucose is normalized after delivery. 
Since significant insulin resistance of pregnancy develops only in third 
trimester, gestational diabetes sets in only in this period .presence of 
glucose intolerance in early pregnancy indicates preexisting type 1 or 
type 2 diabetes. Women having gestational diabetes are at higher risk 
to develop type 2 diabetes during later part of their life. 
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DIAGNOSIS OF DIABETES22 
Criteria for Diabetes Diagnosis 
HbA1C ≥6.5% 
Perform in lab using NGSP-certified method and standardized to 
DCCT assay 
FBS ≥126 mg/dL 
Fasting defined as no caloric intake for ≥8 hrs 
2-hr PG ≥200 mg/dLduring OGTT (75-g) 
Random PG ≥200 mg/dL 
In persons with symptoms of hyperglycemia or hyperglycemic crisis 
In the absence of unequivocal hyperglycemia results should be 
confirmed using repeat testing 
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HISTORY OF HbA1C 
Gabbay et al.,in 1976 suggested measurement of glycosylated 
hemoglobin as an   diabetic control. 
Allan et al., in 1958, described a group of minor hemoglobins 
that can be separated from HbA1C,the major hemoglobin by ion 
exchange chromatography. These minor hemoglobins were designated 
as HbA1A,HbA1B and HbA1C – collectively called HbA1(a+b+c) or 
HbA1, the so called glycosylated hemoglobin 
Increased levels of glycosylated hemoglobin was observed by 
Huismann Dozy in diabetic patients in 1992. 
In 1975 it was demonstrated by Flucckinger and Winterhalter 
that HbA could be formed in vitro, by incubating either whole blood or 
purified hemoglobin at 37 degree celcius in the presence of 
hemoglobin. The relation between blood sugar and HbA1c was 
demonstrated by Koenig and Cerami in 1975. In 1976 Tattersal et al. in 
their twin study observed that metabolic abnormality led to an 
increased level of HbA1C in diabetes rather than a genetic marker. In 
1993 DCCT trial observed a relation between type1 diabetes and 
HbA1C in 1998 UKPDS trial established the relationship between 
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type2 diabetes and HbA1C. In2010 ADA recommended HbA1C in the 
diagnosis of diabetes and pre-diabetes. 
Hemoglobin A constitutes 90% hemoglobin of children more 
than six months of age and adults.HbA1C is the most abundant of the 
minor hemoglobin components, that is separated when HbA is passed 
through a chromatographic column. Except for the hexose group linked 
to the N terminal amino acid of the beta chain, the HbA1C is 
structurally similar to HbA. This is called the glycosylated 
hemoglobin. Normal value of HbA1C dependents on the methodology 
used and also varies from lab to lab. 
Structure and biosynthesis  
Post-translational, non-enzymatic slow glycosylation of HbA 
within the RBC leads to the synthesis of HbA1C which occurs 
throughout the life span of hemoglobin in circulation that is around 120 
days.HbA1C is formed in a two stage process. The first stage includes 
the formation of a week attachment between the amino group of HbA 
and glucose by a Schiff base. This is called pre-HbA1C. In the second 
stage an Amadori reaction takes place which leads to a molecular 
rearrangement of aldamin which leads to the formation of ketamine in 
which glucose molecule is attached to hemoglobin forming HbA1C. 
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The preHbA1C stage seems to be rapid and reversible whereas 
HbA1C,the second stage is slow and irreversible23,24,25. 
FIGURE1: STRUCTURE OF HEMOGLOBIN A1C 
 
FIGURE 2 : N TERMINUS OF BETA CHAIN 
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FIGURE 3 : FORMATION OF HbA1C 
 
HbA1C is formed slowly and almost irreversibly by the 
condensation of glucose and Hb in RBC. With simultaneous 
accumulation of HbA1C it is evident that the amount of HbA1C should 
be a reflection of average glucose concentration seen by the RBC’s 
during their life span.  
1% of HbA1C was reported to represent 35mg % of blood 
glucose levels by Goldstein in 198426. Similarly a formula was derived 
from univariate analysis by Svendesen et al. In 1982 such as 
HbA1C=2.07 X [mean blood glucose]0.596. These formulas are not 
for general use because of methodology differences and acute 
fluctuations in blood glucose. 
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When properly assayed HbA1C% provides a good cumulative 
index of glycemic control for a preceding period of 3 months. 
 Glucose in HbA1C gets attached to the beta chain of HbA to its 
N terminal which is also as site for 2,3 Diphosphoglycerate 
[2,3DPG],which is the regulator of hemoglobin function . High affinity 
for oxygen is seen in HbA1C. Therefore in diabetes with increased 
glycated hemoglobin and relative deficiency of 2,3 DPG  can result in 
decreased oxygenation of tissues .this forms one of the pathogenic 
hypothesis of microvascular complication including retinopathy27. 
Advantages of HbA1C ESTIMATION  
1. It’s a simple procedure.  
2. No need for dietary preparation. 
3. It eliminates the variability noted with glucose tolerance test. 
4. There is a reasonably accurate reflection of overall chronic 
hyperglycemia. 
5. Duration of diabetes, weight and sex does not affect HbA1C 
levels. 
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Disadvantages of HbA1C estimation  
1. The rate of formation of glycosylation is much faster than its 
disappearance. 
2. Results dependent on methods used  
3. No internationally accepted standard is not available yet. 
Conditions leading to false elevation of HbA1C. 
A. Chromatographic abnormalities  
1. Hyperlipidemia [due to lactescence] 
2. Elevated temperature and or buffer Ph. 
3. Negatively charged Hb variants ,such as HbF 
4. Acute hyperglycemia[fast glycosylation] 
B. Other posttranslational modification of hemoglobin 
1. Aspirin[acetylation] 
2. Antibiotics[penicilloylation] 
3. Alcohol[5-deoxy-xylulose-l-PO4] 
4. Uremia [carbamylation] 
 Conditions leading to falsely low HbA1C levels  
A. Chromatographic abnormalities  
1. Low temperature and or buffer Ph. 
2. Positively charged Hb variants such as, Hb S or HbC. 
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B. Altered RBC dynamics  
1. Increased destruction of RBCs-hemolytic anemia 
2. Active erythropoiesis as in pregnancy  
3. Recent blood transfusion. 
Conditions leading to falsely high values of HbA1C 
1. Iron deficiency anemia 
2. Vitamin B12 deficiency  
3. Folate deficiency 
Methods for measuring glycosylated hemoglobin28 
1. Chromatographic methods[Kynoch and Lehmann] 
2. Colorimetric method[Fluckiger and Winterhalter]                                      
3. Radioimmuno assay , 
In the 1990s, after the publication of the DCCT trials the American 
diabetes association began to make treatment recommendations on 
the basis of HbA1C. Presently HbA1C has become the gold standard 
for diabetic management in both clinical and research settings29.The 
ADA recommends HbA1C less than 7% as the glycemic control 
goal. 
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Platelets are small anuclear cell important in haemostasis and 
thrombosis30.In 1841 Addison described platelets as extremely minute 
granules in clotted blood. Bizzozero coined the term platelets and 
observed there  adhesive quality with increased stickiness  once vessel 
wall is damaged platelets have a characteristic discoid shape and are 
formed from the cytoplasm of megakaryocytes younger platelets have 
more functional ability .10 3 to 10 11 platelets are formed by each 
megakaryocytes 
Platelet formation  
Megakaryocytes residing primarily in the bone marrow,also 
found in lung and peripheral blood are rare myeloid cells which 
constitute less than 1 % of the myeloid cells.  In early development, 
megakaryopoiesis occurs in the yolk sac and the fetal liver. The 
pluripotent stem cells megakaryocytes develop into two types of 
precursors, burst forming cells and colony forming cells. CD34 antigen 
is expressed on both the types of megakaryocytic precursors31. 
Thrombopoiesis is primarily regulated by the cytokine, 
thrombopoietin, to maintain a constant platelet mass.  Thrombopoietin 
is thought to act along with other factors like IL-3,IL-6 and IL-11 
although they are not essential for megakaryocytes maturation. 
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The platelets were identified over 120 years ago but the 
mechanism of platelet genesis has not attained a consensus .A modified 
flow model of platelet formation has been recently supported by 
evidences. In this model, proplatelets, an intermediate pseudopodial 
extentions are essential in platelet formation. Proplatelets are formed 
by evagination of the mature megakaryocyte’s extensive internal 
membrane system .this concept was first introduced by Wright in 1906 
where he describes platelet detachment from megakaryocytes 
pseudopods. The platelet formation from megakaryocytes involves the 
conversion of the cytoplasm into 100 to 500 micrometer long branched 
proplatelets over which individual platelets are formed. Generally a 
single site on megacaryocytes one or more pseudopodia develops 
forming proplatelet and then platelets. About 4 to 10 hours the 
pseudopodia continuously elongate and taper into proplatelets of an 
average diameter of 2 to 4 micrometer. Further proplatelet generation 
continuous at or near the initial site of proplatelet formation and in a 
wave like manner spreads throughout the rest of the cell till the 
cytoplasm of the megakaryocytes is completely converted into a 
complex and extensive network of interconnected proplatelets. The 
megakaryocytes cell body with multilobed nucleaus is compressed into 
a central mass without cytoplasm and ultimately extruded and 
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degraded .The events involved in platelet formation from proplatelets 
have not been identified precisely. 
FIGURE 4: ELECTRON MICROSCOPIC PICTURE OF PLATELET  
 
FIGURE 5: PLATELET FORMATION 
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Platelets have an average life span of 7 to 10 days. Platelets are 
removed from circulation mainly by two mechanism, firstly by 
senescence or by an endothelial supportive function of random removal 
of fixed fraction of platelets of about 7.1 * 10 9 per liter per day. 
Splenic macrophages primarily remove the senescent platelets. 
Hepaticmacrophages quickly remove severely damaged platelets 
because of the larger blood flow through the liver32. Accumulation of 
surface IgG is assumed in aging platelets containing decreased levels 
of sialic acid 33. 
Wright –stained smears reveal platelets to be small, anuclear 
measuring about 2 micrometer diameter and 8 fl volume 
approximately34,35. 
Platelets exist in resting and activated forms.  The activated form 
results from agonist stimulation [i.e., response to thrombin]. The 
resting state form has a base line metabolic activity. Most information 
on platelet anatomy is derived from transmission electron microscopy. 
The platelet structure is classified into four, the platelet surface, 
membrane structures, cytoskeleton and granules36. 
The platelet plasma membrane, a typical 20 mm thick trilaminar 
structure which separates extra cellular and intra cellular regions37 . 
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Although the platelet plasma membrane appears similar to that of other 
blood cells, the platelet membrane is complex in composition, function 
and distribution. The phospholipid bilayer of the platelet membrane 
incorporates a number of glycoprotein and lipids. This helps the 
membrane in integrating a variety of intra and extra platelet evens like 
permeability, platelet adhesion, aggregation and agonist stimulation. 
Glycocalyx, a 15-20 mm thick, layer of lipid, sugars and 
proteins covers the outer surface of platelet plasma membrane. The 
platelet glycocalyx coats the surface connected canalicular system and 
interacts with both cellular and plasma components of blood and blood 
vessels. The platelet glycocalyx provides a transfer point by 
endocytosis for plasmaprotein such as fibrinogen38,39.The platelet  
glycocalyx  contains glycolipids, absorbed plasma proteins ,glycolipids 
, mucopolysaccharides 40,41. The glycocalyx has anet negative charge 
mainly due tosialic acid residues oncertainproteins like gp1. This 
negative charge is considered to be the reason tominimize the 
attachment of circulating platelets to each other and to the vessel wall. 
 Platelets have a high content of actin and their contractile 
response during activation relates it to be like muscle   cell .muscle like 
properties are seen in two membranous system of platelets , dense 
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tubular system and surface connected canalicular system, resembling 
sarcotubules and transverse tubules , respectively42. 
The shape of the platelet and its ability to contract and spread is 
determined by cytoskeleton which is constituted by a cytoplasmic 
framework of monomers, tubules and filaments43.platelets change their 
shape and produce extracellular extensions and collect and extrude 
secretory granules thus affecting surface activity .the varied functions 
of platelets are performed by 3 separate structures membrane skeleton 
covering the plasma membranes in a surface ,the actin and intermediate 
filaments also called solgel zone which fills the cytoplasm ,and finally 
circumferential microtubule encircling the platelets and produce the 
resting disc-like  form44. 
Normally platelet function require an amplified or accentuated 
stimulus to get an appropriate response .this purpose is served by the 
secretory granules which release of additional stimulatory materials 
which are previously stored within the resting platelet. The dense 
bodies and the alpha granules appears to be the two main secretory 
granules with their highly reactive readily available contents like 
adenosine diphosphate and fibrinogen 45.platelet metabolic activity 
dramatically increased once the platelet granule secretion begins. A 
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wave of calcium released and is marked by increased adenosin 
triphosphate production46,47.  
Small granules 90nm in diameter, demonstrable with alkaline 
diaminobenzidine due to their catalase activity are the 
microperoxisome 48.the microperoxisomes may participate in the 
synthesis of platelet activating factor. The ultimate fate of the 
microperoxisomes in the platelet cytoplasm is not known49.platelet 
organelles, distinguished by electron dense bristle coat are coated 
vesicles of 70 to 90 nm diameter. The surface coat is formed by 
clathrin .the special staining reveals that the same polyhedral surface 
coat is same as that in the plasma and the surface connected 
cannalicular membrane found on the coated pits and vesicles50. The 
platelet mitochondria are smaller in size otherwise similar to those in 
all other types. There are approximately seven per human platelet. 
They serve as the action site for respiratory chain and citric acid 
cycle51. Glycogen plays an important role in platelet metabolism and is 
found in small particles or masses of closely associated particles52.  
There are various functions of platelets which include adhesion, 
aggregation, secretion, clot retraction and procoagulant activity 
.vascular damage leads to the exposure of subendothelial matrix 
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protein which initiates platelet adhesion. The rate of shear affect the 
platelet glycoprotein receptor which mediates adhesion. Recruitment of 
circulating platelets into thrombus is also a part of adhesion53. 
The platelets when activated attains spherical shape and extend 
psueudopodia which enable them to attach to other platelets and vessel 
wall. The spherical transition increases the platelets optical density. 
The shape change occurs as a consequence of increased intracellular 
calcium ions which activates myosin light chain kinase or by inhibition 
of myosin light chain phosphatase mediating phosphorylation of 
myosin light chain, which is regulated down stream of Rho kinase. 
The cross linking of platelets through fibrinogen binding , or 
other bivalent or multivalent ligands like vWF to the integrin alpha 2b 
beta3  on adjacent  
The different type of granules contains distinct contents that 
display varied roles in hemostasis. The dense or alpha granule 
deficiency is the basis of secretory disorders associated with excessive 
bleeding. 
The assembly of two multiprotein complex, namely the tenase and 
prothrombinase complexes play a vital role in coagulation cascade and 
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provide a negatively charged phospholipid surface an important 
function, thus enabling platelet activation for its critical function. 
Procoagulant activity is described as the formation of negatively 
charged lipids surface on activated platelets. This is formed by 
phosphatidyl serine movement to the outer leaflet from the inner of the 
platelet membrane. 
Platelet activation leads to the generation of platelet derived 
microparticles seen together with an increase in procoagulant activities. 
Calcium entry is required for the formation of platelet micromolecules 
and is seen in response to stimulation by calcium ionophore which 
requires high agonist concentrations and favorable conditions for them 
to be formed upon receptor activation. 
Clot retraction: it is a known fact for more than 2 centuries over 
a time course to minute to hours blood clot retracts. This clot retraction 
helps the platelet rich thrombus to withstand high shear forces found in 
small arterioles and other vessels. After addition of thrombin, thrombin 
–stimulated platelet rich plasma can be measured readily for clot 
retraction. 
The peripheral blood quantification of platelet count is a well-
recognized tool. Several indices have been derived from platelets the 
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most common of them being platelet distribution width and mean 
platelet volume. Platelet parameters like, mean platelet volume[MPV], 
platelet distribution width [PDW],plateletcrit [PCT], platelet to large 
cell ratio [PLCR],can be measured by the use recent advanced 
automated blood cell analyzers. These measurements provide some 
important information but are not yet accepted for routine clinical 
use54. 
MEAN PLATELET VOLUME[MPV] 
Peripheral blood platelet counts does not reveal much about 
platelet related haemostatic function unless there is a severely low 
platelet count. But most automated blood analyzers measure an 
important platelet parameter, the mean platelet volume which is a 
clinically useful pathophysiological information on vascular diseases 
of a patient55. 
PHYSIOLOGY OF PLATELET SIZE 
Mean platelet volume appears to be a determinant or a marker of 
platelet function. In vitro large platelets are more reactive when 
compared to small platelets. The larger platelets aggregate more 
rapidly to platelet agonist such as adenosine diphosphate, collagen and 
adrenaline lead to production of vasoactive factors such as arachidonic 
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acid metabolites, serotonin, adenosine triphosphate and beta 
thromboglobulin. The large platelets have high LDH activity and 
contains more dense granules. They are associated with a decreased 
bleeding time56. 
MEAN PLATELET VOLUME IN DIABETES 
Mean  platelet volume is related to platelet aggregation, both in 
whole blood and in platelet rich plasma, in population in some subjects 
or some disease state like diabetes, heart diseases. Increased levels of 
adhesion molecules like Pselectin,glycoprotein2b 3a has been 
recognized in large platelets although the surface density of the 
glycoprotein is usually constant and is not affected by the platelet 
volume.  
Platelets, anucleate cells, have no protein synthetic capacity. 
Platelets are heterogeneous with regard to their hemostatic potential, 
density and size. It was believed that platelet size decreased with age. 
The recent evidences favor the platelet precursor cell, the MK, 
determine the mean platelet volume and other parameters, protein 
content and reactivity at or before thrombopoiesis. Among the 
mammalian cells MK’s are unique in that they are polyploid.  This 
means that the MK cells can double their DNA content by a process 
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termed endomitosis without a full mitotic cell division. MK’s produce 
a population of cells whose ploidy range from 4N to 128N,(2N 
represents normal diploid state) undergoing a varying number of 
endomitotic division. The model ploidy in the majority of mammal 
studied 16N is the most common studied till date .each MK cell 
produce about 1000 to 2000 platelets probably  by cytoplasmic 
fragmentation of MK’s in  pulmonary circulation .  MK and platelets 
are considered a single system by the name, the megakaryocyte-
platelet hemostatic axis[MPHA]. In  normal population the platelet 
count is inversely   proportional to mean platelet volume, the product 
of mean platelet volume and platelet count is a near constant – called 
platelet mass, platelet mass is related to bleeding time and bleeding 
time is inversely proportional to MK size and ploidy . In the absence of 
platelet production, when acute platelet destruction occurs the MK 
ploidy remains unaffected whereas mean platelet volume increased 
.When platelet production and destruction occurs at the same time both 
mean platelet volume and MK ploidy increases. When platelet 
production along is increased MK ploidy is increased. This leads to the 
postulation that regulation of MK ploidy and hence platelet count and 
mean platelet volume are under different hormonal control. Variations 
in MK ploidy and size and cytoplasmic volume are related to the 
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change in platelet production whereas variation in mean platelet 
volume results from a change in the platelet destruction rate. 
The ideal method for measuring the volume of platelet utilizes 
the changes in light diffractions and electrical impedance when platelet 
pass through a narrow aperture. In Coulter hematology analyzers 
electrical impedance method is used whereas light diffraction is used 
by technicon. Semi-quantitative measurements of diameter of platelets 
on platelet smears or using flow cytometry are less satisfactory 
methods to measure platelet volume. 
In coulter series a voltage change is created proportional to the 
particle size when the cells held in fluid suspension are flown through 
a small aperture. A raw histogram is generated and a log-normal curve 
is fitted to the data .using numerical integration platelet count and 
mean platelet volume is calculated57.in the Sysmex measures cells in 
fluid suspensions, similar to Coulter series although in addition cells 
are hydro-dynamically focused so that cells travel in a straight line 
through the aperture. This prevents spurious changes in electrical field  
caused by the cells flowing throw  at the edge of the aperture. It defers 
from coulter also because the upper and lower discriminators are both 
mobile. The distribution curve obtained is not a fitted curve but an 
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actual data. the formula used to calculate mean platelet volume is 
[MPV(fl)=Pct(%)*1000/Plt(103/microliter).the laser –optic technology 
is used to measure the granularity and size of cells in suspension by the 
Technicon instruments. In this method a beam of light is passed 
through the cells and sides scatter is proportional to density or 
granularity and forward  scatter is proportional to the size of particles . 
mean platelet volume is calculated as the mean after the data is plotted 
on a platelet histogram.  
A cross sectional study was conducted by Dow university of 
health science Karachi Pakistan by Zuberi B F et al in 2006-0758. 
Diabetes mellitus is a prothrombotic state with increased 
activation of platelets and coagulation proteins and decreased 
fibrinolytic activity 59.the differences in platelet  
Function in diabetic and non-diabetic population is called 
diabetic thrombocytopathy. Enhanced platelet aggregation is seen in 
diabetic patients in the early course of disease. Certain abnormal 
features exhibited by the platelets of diabetic patients make them more 
prone to thrombotic episodes 60 
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Enhanced Platelet activation 
The in vivo activation of circulating platelets in diabetic 
individuals have been studied widely61.Most reports hypothesise a 
specific priming of hyper sensitive platelets in diabetics in response to 
platelet agonists. More frequent episodes of release of their granules 
occurs in circulating platelets. Platelet survival is reduced due to their 
accelerated sequestration in the circulation implied by augmented 
granule release. Increased thrombopoiesis is reflected by the increased 
platelet turnover in diabetic patients.62,63 
Altered response to agonists, increased fibrinogen binding, 
enhanced glycoprotein receptors expression, decreased membrane 
fluidity, and increase in adhesive proteins on the platelet surface is 
instrumental in platelet activation. 
Platelets hyper-aggregability 
Glucose responsive platelets hyper aggregation was recognized 
in 1965.64 When compared to non-diabetic individuals, diabetics 
exhibit an enhanced platelet aggregation in response to thrombin, 
collagen, arachidonic acid epinephrine and adenosine diphosphate65. 
After stimulation with platelet agonists these platelets show reduced 
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threshold for platelet aggregation under in vitro conditions.66In diabetic 
patients associated with macro vascular disease, increased platelet 
aggregation is more apparent.67 Increased adhesiveness and increased 
spontaneous aggregation and also increased aggregation on extra 
cellular matrix is seen in platelets of diabetic individuals. 
Increased arachidonic acid metabolism 
Thromboxane A2 is one of the most potent of platelet activators. 
Accelerated calcium mobilization occurs as a result increased protein 
phosphorylation, enhanced inositol triphosphate production which 
itself results from an enhanced activation of arachidonic acid pathway 
leads to increased thromboxane A2 formation, and increased 
phosphoinositide turnover resulting in increased protein 
phosphorylation68. 
Increased Thromboxane A2 production has been reported in both in 
vitro and in vivo conditions in diabetic patients. Increased TXA2 
synthesis in vitro is noted when platelet agonist is added to platelet rich 
plasma69. Increased thromboxane metabolism in vivo is supported by 
the presence of increased urinary excretion of 11-dehydro-
ThromboxaneB270,71. 
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Thromboxane metabolism is directly affected by plasma glucose 
concentration and HbA1c. Reduced thromboxane A2 production has 
been identified in several studies with improved glycemic control but 
not in all studies72,73. Micro and macro angiopathy associated with 
diabetes has been related to increased production of thromboxane A2. 
Increased calcium flux 
Abnormal calcium homeostasis is exhibited by the Platelets of 
patients with type 2 diabetes mellitus. High levels of intracellular free 
calcium is seen in patients with diabetes mellitus along with increased 
calcium mobilization from intra-platelet storage pool74,75. The 
decreased membrane fluidity is attributed to the free intracellular 
calcium. Altered properties of platelet membranes in platelet hyper 
function is correlated to calcium mobilization.76Intracellular 
magnesium concentrations are reduced along with alterations in 
platelet calcium homeostasis consistent with an increase in platelet 
adhesiveness and hyperaggregability.77 
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Platelets nitric oxide synthesis 
Platelet endothelium interactions and endothelium mediated 
vasodilatation is inhibited by Nitric oxide (NO) and prostacyclin. In 
Diabetic patients platelets 
 NO and prostacyclin production is decreased. Concentration of 
NO is decreased in the platelets of diabetic patients when compared to 
non-diabetic individuals.78NO synthesis in platelets is stimulated by 
insulin.79 
Platelet secretary products 
Mitogenic and chemotactic factors like platelet-derived growth 
factor, transforming growth factor-β , vascular endothelial growth 
factor, basic fibroblast growth factor ,platelet derived epidermal 
growth factor (PDEGF) and insulin-like growth factor-1 (IGF-1) are 
released by activated platelet. Platelet factor-4 (PF-4), plasminogen 
activator inhibitor-1 (PAI-1), von Willebrand factor, β-
thromboglobulin, fibrinogen, fibronectin and thrombospondin are also 
significantly released upon platelet activation.80 Elevated plasma levels 
of thromboglobulin and Platelet factor 4 is in patients with diabetes 
mellitus.81 
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Platelet membrane glycation 
The non-enzymatic glycation of platelet membrane proteins is 
affected by hyperglycemia. This Non-enzymatic glycation of platelet 
membrane proteins produces alterations in the protein structure, 
conformation and membrane lipid dynamics.82,83,84 Reduced platelet 
membrane fluidity also seems to be related to the extent of glycation of 
membrane proteins. Enhanced expression of receptors results from 
altered dynamics of platelet membrane lipids thus affecting the platelet 
functions. The receptors whose expression is enhanced includes 
Pselectin,fibrinogen receptors and von Willebrand factor 
receptors.85,86The increased expression of adhesion receptors, like, 
alpha2beta3 ,results in frequent episodes of platelet activation and 
degranulation. Increased expression of these adhesion receptors makes 
the platelets more susceptible topotential ligands.87 
Membrane glycation of low density lipoproteins 
Low density lipoproteins (LDL) glycation has been shown to 
increase platelet sensitivity to aggregating agents.88The degree of low 
density lipoprotein glycation is proportional to the rate of platelet 
aggregation.Increase in non-enzymatically glycated is caused by 
hyperglycaemia which in turn renders the platelets more susceptible to 
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oxidative stress.89,90Non-enzymatically Glycated LDL inhibits platelet 
membrane Calcium ATPase which results in increased intracellular 
Calcium concentration and decreased nitric oxide synthase 
activity.91Glycated LDL leads to inhibition of platelet membrane 
Na+/K+- adenosine triphosphatase activity is and result in platelet 
dysfunction.92 Lipoproteins also increase thromboxane generation 
during platelet activation.93The activation of prothrombinase complex 
in diabetes mellitus is increased by oxidized lipids by providing a 
surface for activation. 
Expression of increased surface markers on platelet membrane 
 Several platelet specific glycoprotein receptors are increased in 
number, adhesiveness and activity in diabetic patients. In diabetic 
patients an increased level of GPIIb/IIIa (αIIbβ3), GPIb-IX-V, 
GPIa/IIa, CD62 and CD63 have been observed94,95,96. Increased 
expression of platelet αIIbβ3 is consistent with enhanced fibrinogen 
binding and aggregability in patients with diabetes.97Platelet receptor 
activation has been correlated with glycaemia and also with vascular 
complications.98Enhanced surface expression of these adhesion 
molecules suggests that platelets also communicate with leukocytes. 
Platelets play an important role in inflammation mediated tissue 
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damage in the vessels. In diabetic patients an up-regulation ofCD40-
CD40 ligand system has been observed.99CD40Ligand levels on 
platelets corresponds with the high HbA1c levels. P-selectin and 
CD40Ligand are shed into plasma in biologically active soluble form 
from the platelet surface .100,101  Increased levels of soluble P-selectin 
and CD40Ligand are seen in patients with diabetes mellitus and 
cardiovascular diseases.102,103,104 Elevated levels of these compounds 
may reflect a prothrombotic state and also accelerated 
atherosclerosis.105,106,107 
Hypersensitivity to collagen is exhibited by platelets of patients 
with diabetes mellitus. Increased collagen-induced aggregation 
correlates with the elevated expression of platelet Fc-receptor.108,109 
Platelet metabolic alterations 
Glucose entry into the platelets is not dependent on 
insulin,therefore intra-platelet glucose concentration reflects the extra 
cellular glucose concentration.110Hyperglycaemia is a definite causal 
factor for in vivo platelet activation and platelet hyperactivity in 
diabetic patients.111 
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Hyperglycaemia induces an increased activation of platelets exposed to 
high shear stress both in vitro and in vivo.112 Impaired calcium 
homeostasis, activation of PKC, decreased production of platelet-
derived nitric acid and increased formation of superoxide anion leads 
to increased sensitivity to agonists and metabolic alterations of 
platelets. Reduced glutathione levels and nitric oxide synthase activity 
are the few other metabolic alterations in the platelets diabetic 
patients.113,114 
Altered platelet size and volume 
 Predominantly large platelets circulate in the blood of diabetic 
patients. This is considered secondary to increased ploidy and 
activation of megakaryocytes.115Larger and younger platelets are 
considered to be more reactive. 
Mean platelet volume (MPV) corresponds to the number of 
glycoprotein molecules on the platelet membrane, the thromboxane 
synthesizing capacity and platelet granule contents of various platelet 
specific protein. 
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Platelet life span 
Platelet survival in patients with diabetes mellitus have produced 
conflicting results in various studies. Some studies show a decreased 
platelet survival in patients with diabetes mellitus with presence of 
vascular complications.116While a few studies did not find any 
difference in platelet survival and vascular complications with diabetes 
mellitus compared to normal healthy controls.117 
Platelet-leukocyte interaction 
 Inflammation and thrombosis cause activation of endothelial 
cells, leukocytes and platelets. Complex interaction between these cells 
is influenced by several mediators. 
Platelets may influence leukocyte activation, chemotaxis and 
phagocytosis. Platelet-released adenine nucleotides and platelet derived 
growth factor induce leukocyte degranulation. Adherent platelets, 
platelet-derived micro-particles, PDGF, PF-4 and TXA2 enhance 
leukocyte rolling and adhesion.65 PDGF is also a chemo attractant and 
enhances phagocytosis by neutrophils and monocytes. Superoxide 
formation by neutrophils may be enhanced by platelets bound to 
neutrophils or platelet-released ADP while intact non stimulated 
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platelets may inhibit neutrophil superoxide production.118 Leukocyte 
chemotaxis, adhesion and superoxide generation are inhibited by P-
selectin and nitric oxide released from platelets.119 
Platelets and platelet-derived products influence leukocyte 
function in several ways. Platelets and leukocytes may form platelet-
leukocyte aggregates or conjugates (PLAs) mainly via platelet-
expressed Pselectin and its receptors P-selectin glycoprotein ligand- 1, 
CD15, αIIbβ3 and CD11b/CD18. Diabetic angiopathy involves 
atherosclerosis, inflammation and thrombosis due to abnormal function 
of platelet and leukocyte. In diabetic microangiopathy increased 
platelet and leukocyte activation and heterotypic aggregation are 
evident.120 
MPV AND ANTIPLATELET DRUGS 
Platelet aggregation is an essential step in physiological 
hemostasis and is involved in vascular pathology such as 
atherosclerosis, arterial thromboembolism, unstable angina pectoris, 
myocardial infarction, transient ischemic attacks and stroke121.the 
inhibition of platelet aggregation, example by aspirin, has become an 
important treatment for unstable angina pectoris and transient ischemic 
attack and secondary prevention of myocardial infarction and stroke.  
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Aspirin inhibits platelet aggregation through an irreversible inhibition 
of the cyclooxygenase. It is not known whether this impairment of 
platelet function has an influence on the feedback control system of 
platelet production and hence on platelet count and platelet volume. 
Stephen Erhart et al studied the influence of aspirin on platelet count, 
volume and total platelet mass in vitro and in a randomized double 
blind placebo control in 20 healthy young male volunteers in vivo. The 
platelet count was unaffected by increasing concentrations of aspirin in 
vitro over 4 hours, indicating that there was no platelet destruction by 
aspirin even with the high concentration of 250 microgram per ml 
which is well above concentration reached in vivo usually. The platelet 
volume was unaffected by aspirin and remained constant over time. In 
vivo studies showed that repeated blood sampling during a seven day 
treatment with 250 mg aspirin daily showed an increased platelet count 
and total platelet mass. An increased platelet count and mass were also 
in the placebo group on day four. Because of this observation the study 
was repeated with a minimal volume taken only on day four. 
Surprisingly both aspirin and placebo had not effect under this 
condition. Therefore, they stated that aspirin treatment together with 
repeated small bleeding increased platelet count and mass, but not 
aspirin treatment by itself. Aspirin treatment without repeated blood 
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withdrawal had no effect. These data indicate that aspirin may affect 
the circulating platelet mass under certain conditions. 
MPV AND AGE 
It was used to be thought that the platelet size decreased with 
age, but more recent evidence suggest that MPV and other platelet 
parameters  and therefore platelet protein content and reactivity, are 
determined primarily at or before thrombopoesis by the platelet 
precursor cell, the MK. 
MPVAND GENDER  
Gender dependent differences in platelet count have been 
demonstrated in few studies. In female patients platelet count is higher 
than in the male population, which seems to show the hormonal 
variations or an alternate mechanism associated with normal cycle. 
Anna M Butkiewicz et al122conducted a study on healthy blood donors 
divided into groups of the two gender.  Platelet count and mean platelet 
volume were determined on a hematological analyzer. Higher platelet 
count was noted in the group of women as compared to men. At the 
same time women had lower thrombopoietin concentration compared 
to men. No statistically significant difference were found in the mean 
platelet volume, though there was a slight increase in females. 
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MPV AND HYPERTENSION 
MPV a determinant of platelet function, is a recently found risk 
factor for atherothrombosis. Coban et al selected essential hypertensive 
patients, 36 white coat hypertensive subjects and 36 normotensive 
control subjects match for age, gender, and BMI. MPV was 
significantly higher in essential hypertensives and white coat 
hypertensives than in normotensives:it was also higher in essential 
hypertensives than in white coat hypertensives.123 Platelet counts were 
not different among the study group. MPV was positively correlated 
with ambulatory diastolic blood pressure in essential hypertension and 
white coat hypertension group. Platelet size is also found to be elevated 
in individuals with hypertension and diabetes mellitus, both conditions 
that predispose to the development of vascular disease. 
MPV AND METABOLIC SYNDROME 
Giuseppe Lippi et al performed a retrospective analysis on the 
data base of the laboratory information system of the clinical chemistry 
laboratory in Italy. Data for MPV, blood glucose, lipid profile values 
were retrieved from all outpatients consecutively referred by a general 
practitioner for routine blood testing. Cumulative results for lipid 
profile, MPV, blood glucose were retrieved for two years. The mean 
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MPV of subjects with all biochemical markers suggestive of the 
metabolic syndrome was slightly higher but not significantly different 
from that of control subjects. 
MPV AND SMOKING 
Tobacco smoking is one of the major factors accelerates 
atherosclerosis. Deleterious effects of smoking are associated with 
generation of free radicals that breakdown nitric oxide, which on the 
one hand enhances thromboxane synthesis, but on the other reduces 
production of prostacyclin, thus leading to clotting disorders, 
additionally enhanced by increased production of fibrinogen and factor 
seven. Butkiewicz AM et al designed a study to assess platelet 
parameters in smoking healthy subjects with reference to sex. 124All the 
subjects were tested for platelet count, MPV, percentage of large 
platelet, concentration of thromboglobulin,P selectin and 
thrombopoietin, percentage of reticulate platelet and absolute count of 
reticulated platelet. In neither of the sexes smoking had an effect on 
MPV, percentage of large platelets, concentration of thrombopoietin, 
absolute count of reticulate platelet and concentration of 
thromboglobulin. 
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MPV AND ISCHEMIC HEART DISEASE 
A study done by MM Khandekr and AS Khurana et al on 
patients diagnosed with unstable angina or acute myocardial infarction 
diagnosed on the basis of history, characteristic of electrocardiographic 
changes and increased cardiac enzyme activities. MPV, platelet 
distribution width and platelet large cell ratio were significantly raised 
in patients with acute myocardial infarction and unstable angina. 
Larger platelets are hemostaticaly more active and a risk factor for 
developing coronary thrombosis, leading to myocardial infarction. 
Patients with larger platelets can easily be identified during routine 
hematological analysis and could possibly benefit from preventive 
treatment.125 
MPV AND STROKE 
In some pathologic condition the megakaryocyte platelet 
hemostatic axis is chronically or acutely perturbed resulting in the 
production of hyper functional platelets which may be involved in 
subsequent vascular disease or an acute thrombotic event such as 
stroke. There is evidence that platelet function is accentuated in acute 
ischemic stroke. Therefore, a fundamental is whether this increase in 
platelet reactivity precedes the stroke, and plays a part in initiating the 
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event, or represents a reactive change to it. The development of 
atherosclerosis involves local platelet adhesion, but whether 
widespread systematic activation of platelet is present is an open 
question. The study of MKs and platelets in acute stage within 36 
hours of onset of stroke would yield valuable information on the 
subject. MPV measured at this stage may well reflect, at least in part, 
the potential reactivity of platelets prior to the stroke. However, the 
dynamics of platelet consumption and production in the acute phase of 
stroke are not yet understood well enough to rule out the possibility 
that MPV is being modified to some extent by the acute destruction of 
platelets and subsequent change in the fragmentation of MK 
cytoplasm. If MK parameters could be shown to the abnormal shortly 
following the stroke this would strongly suggest that the MPHA was 
chronically perturbed prior to the stroke126. Increased platelet function, 
and in some cases a shift in MK indices in a pro-thrombotic direction 
has been shown in stroke risk factors such as hypertension, 
hypercholesterolemia, diabetes mellitus and smoking and in vascular 
condition associated with stroke such as atherosclerosis, peripheral 
vascular disease and myocardial infarction. Thus it seem probable that 
in patients with certain risk factors profiles systemic platelet activation 
precedes the onset of stroke. 
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In a study done by O’malley et al mean platelet volume was found to 
be high in acute stroke. In addition, platelet count was reduced in 
stroke patients compared with control subjects. Repeated 
measurements of mean platelet volume and platelet count in available 
survivors showed no significant change from the acute phase. Platelet 
changes did not relate to outcome measured at six months.  In 
conclusion, the study has shown an elevation of MPV and reduction of 
platelet count in acute stroke that persist long after the acute event127.  
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MATERIALS AND METHODS 
PATIENT SELECTION  
The present study included diagnosed cases of type 2 diabetes 
patients on treatment from the department of diabetology, Government 
Stanley Medical College and Hospital, irrespective of their present 
glycemic status and the anti-glycemic agent being used for control of 
diabetes. Patients were then grouped into  
INCLUSION CRITERIA 
Confirmed cases of Type 2 DM, who are on treatment. 
 
EXCLUSION CRITERIA 
Cases of Type 1 DM. 
Patients with abnormal platelet counts 
(thrombocytosis/thrombocytopenia)  
Patients on anti-platelet medicines (aspirin, clopidogrel etc.). 
History of blood dyscrasias 
History of thyroid disorders. 
Hb<8g% 
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PLACE OF STUDY 
Stanley Medical College and Hospital, Chennai:  
Department of General Medicine, Endocrinology OPD, Medical wards 
 
SAMPLE SIZE: 100 
 
STUDY DESIGN 
Observational Study 
 
ETHICAL COMMITTEE APPROVAL 
Ethical committee approval was obtained for the study  
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HbA1C 
HbA1C was estimated by immunoturbidometric method. The test 
principle Turbidimetric inhibition immunoassay (TINIA) for the in 
vitro determination of hemoglobinA1c in whole blood is as 
demonstrated in the following diagram. 
 
FIGURE 6: TEST PRINCIPLE FOR HbA1C USING COMPETITIVE 
TURBIDIMETRIC INHIBITION IMMUNOASSAY 
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PRINCIPLE BEHIND ESTIMATION OF MPV WITH SYSMEX SIX 
PART DIFFERENTIAL ANALYZER 
The 6part differential sysmex analyzer is a fully automated 
bidirectional analyzer which performs hematological analysis 
according to the hemodynamic focusing, flow cytometry method 
(using semiconducted laser) and SLS-hemoglobin method. 
 
FIGURE 7: TEST PRINCIPLE BEHIND MPV ASSAY USING 
SYSMEX AUTO-ANALYSER 
Serum cholesterol by CHOD PAP method and HDL and LDL by 
IFCC method in serum collected from plain venous sample. 
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STATISTICALANALYSIS 
The collected data was analyzed with SPSS 16.0 version. To 
describe about the data descriptive statistics frequency analysis, 
percentage analysis were used for categorical variables and for 
continuous variables the mean and S.D were used. To find the 
significance difference between the bivariate samples in independent 
groups the Independent sample t-test was used. For the multivariate 
analysis the one way ANOVA was used. In both the above statistical 
tools the probability value .05 is considered as significant level. 
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 RESULTS 
The study was based on 100 diabetic patients who attended the 
medical and diabetology department of Government Stanley Medical 
College Hospital and who satisfied the inclusion as well exclusion 
criteria were enrolled for this study. 
The collected data was analysed with SPSS 16.0 version.To 
describe about the data descriptive statistics frequency analysis, 
percentage analysis were used for categorical variables and for 
continuous variables the mean and S.D were used. To  find the 
significance difference between the bivariate samples in independent 
groups the Independent sample t-test was used. For the multivariate 
analysis the one way ANOVA with Tukey's Post-Hoc test was used. In 
both the above statistical tools the probability value .05 is considered 
as significant level.  
The detailed statistical analysis was done and the table showing 
the detailed descriptive statistics showing the mean, standad deviation, 
and range is given in the following page.  
The data reveals the mean age of the subjects studied to be 
around 52 years, with amean HbA1C of 8.5 and mean MPV of 8.2. 
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TABLE 1: DESCRIPTIVE STATISTICS 
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Among the 100 patients 58 were female and  42 were males, with an 
average age of 52.12 (SD 9.336), the youngest among the lot being 35 
yrs and the eldest being 70 yrs. 
TABLE 2: DETAILS OF AGE 
 
In studied group,majority of cases were from the age group of 41-50 
years. 
TABLE 3:DETAILS OF AGE RANGE 
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FIGURE1:AGE DISTRIBUTION RANGE 
 
 
FIGURE 2: GENDER DISTRIBUTION 
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TABLE 4: GENDERWISE DISTRIBUTION OF PATIENTS IN 
THE STUDY 
 
 
 
 
Out of 100 patients, 58 were females whereas ,42 were male. Thus 
majority of patients were females.  
TABLE 5:TREATMENT PROFILE 
 
Of the 100 patients studied, the majority were on oral hypoglycaemic 
agents alone(O), a few on both insulin and oral hypoglycaemics (O+I), 
and one person on diet management. 
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FIGURE 3: TREATMENT PROFILE 
 
TABLE 6 :HISTORY OF ALCOHOL 
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FIGURE 4: ALCOHOL EXPOSURE 
 
FIGURE 5: SMOKING HISTORY 
In the population studied around 74 people had either alcohol or 
smoking exposure, of which 70 subjects gave history of both 
alcoholism and smoking.   
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TABLE 7 : HYPERTENSION HISTORY 
 
FIGURE 6 :HYPERTENSION HISTORY 
 
In the population studied, 27% gave a history of hypertension on 
treatment with controlled blood pressure values.  
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TABLE 8 : WEIGHT WISE DISTRIBUTION OF PATIENTS IN 
STUDY 
 
TABLE 9 :BMI RANGE OF PATIENTS IN STUDY  
In the population studied the BMI range of the patients were mainly in 
the range of  24.1-30. Ten percentage were in the range of BMI above 
30. 
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FIGURE 7 :WEIGHT RANGE 
 
FIGURE 8 : BMI RANGE 
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The cholestrol levels in the population was as plotted below in the 
table and figure,with a minimal 22% subjects with undesirable level of 
cholesterol. And among the hundred subjects studied 17 subjects had 
abnormal levels of triglycerides. 
 
TABLE 10 : CHOLESTEROL LEVELS IN THE STUDY 
POPULATION 
 
TABLE 11 : TGL LEVELS IN THE STUDY POPULTION 
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The following tables gives the details of the HDL and LDL levels of 
the subjects in the population studied which shows a low and 
undesirable level of HDL in 17% and 28% showed an elevated levels 
of LDL . 
 
TABLE 12:HDL LEVELS IN STUDY POPULATION 
 
 
TABLE 13 :LDL LEVELS IN STUDY POPULATION 
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FIGURE 9 :CHOLESTEROL LEVELS IN THE STUDY 
POPULATION 
 
 
FIGURE 10 :TGL LEVELS IN THE STUDY POPULATION 
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FIGURE 11 :HDL LEVELS IN THE STUDY POPULATION 
 
 
FIGURE12 :LDL LEVELS IN THE STUDY POPULATION 
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The FBS and PPBS range of the diabetic subjects of the study showed 
71% with poor control of FBS and  44% with elevated PPBS values. 
TABLE 14 : FBS LEVELS IN STUDY POPULATION 
 
 
 
TABLE 15 : PPBS LEVELS IN STUDY POPULATION 
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FIGURE13 : FBS LEVELS IN THE STUDY POPULATION 
 
 
FIGURE14 : PPBS LEVELS IN THE STUDY POPULATION 
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In the population studied 53% of the subjects had an HbA1C of more 
than 8 and  18%  showed a good control of HbA1C  of less than 7. 
TABLE 16 :  HbA1C RANGE  IN STUDY POPULATION 
 
FIGURE 15 :HbA1C RANGE  IN STUDY POPULATION 
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TABLE 17 :MPV RANGE IN STUDY POPULATION  
 
In the population studied the MPV in 77% of the subjects were below 
9fl and the rest of the 23% showed MPV more than 9 fl. 
 
TABLE 18 :COMPARISON OF MPV WITH FBS VALUES 
 
The MPV in the study population was compared with the FBS values, 
with T-test which demonstrated a relation which was not statistically 
significant(p=.199) . 
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TABLE19 :COMPARISON OF MPVWITH FBS VALUES 
STATISTICS 
 
FIGURE 17 : COMPARISON OF MPV IN PATIENTS WITH 
GOOD CONTROL VS POOR CONTROL OF FBS  
 
 
 t value Pvalue Mean Difference Std. Error 
Difference 
MPV -1.293 .199 -.3076 .2379 
-1.459 .149 -.3076 .2108 
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FIGURE 18 : COMPARISON OFMPV AND PPBS 
 
TABLE 19: COMPARISON OFMPV AND PPBS 
 
The MPV in the study population was compared with the PPBS values, 
with T-test which demonstrated a relation which was statistically 
significant(p=.042) . 
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TABLE 20:COMPARISON OF MPV AND PPBS, STATISTICS 
 
TABLE 21 :COMPARISON OF MPV AND TGL 
 
 
 
  t P value Mean 
Difference 
Std. Error 
Difference 
MPV -2.065 .042 -.4433 .2147 
-2.106 .038 -.4433 .2105 
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The MPV in the study population was compared with the TGL values, 
with T-test which demonstrated a relation which was not statistically 
significant(p=.736) . 
 
TABLE 22 : COMPARIS)ON MPV AND TGL STATISTICS 
  t P value Mean 
Difference 
Std. Error 
Difference 
MPV .338 .736 .0979 .2897 
.372 .713 .0979 .2633 
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TABLE 23:COMPARISON OF MPV AND HDL 
 
The MPV in the study population was compared with the HDL values, 
with T-test which demonstrated a relation which was not statistically 
significant(p=.754) . 
TABLE 24:COMPARISON OFMPV AND HDL STATISTICS 
  T test P value Mean 
Difference 
Std. Error 
Difference 
MPV -.314 .754 -.0909 .2897 
-.343 .734 -.0909 .2649 
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FIGURE 19 : COMPARISON OF MPV AND HDL 
 
 
FIGURE 20 : COMPARISON OF MPV AND TGL 
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TABLE 25 : COMPARISON OF MPV AND GENDER 
 
TABLE 26 : COMPARISON OF MPV AND GENDER 
STATISTICS 
 
  T value P value Mean 
Difference 
Std. Error 
Difference 
MPV F 1.725 .088 .3749 .2173 
M 1.756 .082 .3749 .2135 
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FIGURE21:COMPARISON OF MPV AND GENDER
 
 
 
 
The MPV in the study population was compared with gender, 
which showe a higher value of MPV in females compared to the male 
population. But this was not statistically significant(p=.088), when 
analysed by the T-test . 
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TABLE 27 : COMPARISON OF MPV AND HbA1C 
 
 
The descriptive  statistics showing the relation between mean platelet 
volume and HbA1C is shown in the above table with a mean of 8.246 
in the total subjects studied and 8,762  in the subjects with poor control 
(HbA1C > 8%) and 7.289 in the subjects with good glycemic control. 
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TABLE 29 : COMPARISON OF MPV AND HbA1C 
STATISTICS 
(I) HbA1Crange 
Mean 
Difference  
(I-J) Std. Error Sig. 
 
Good 
Control 
 
 
Fair Control 
 
 
-.6077 
 
 
.2759 
 
 
.076 
 
 
Poor Control 
 
 
-1.4734 
 
 
.2508 
 
 
0.0001 
 
 
Fair 
Control 
 
 
 
 
Good Control 
 
 
 
 
.6077 
 
 
 
 
.2759 
 
 
 
 
.076 
 
 
Poor Control 
 
 
-.8657 
 
 
.2124 
 
 
0.0001 
 
 
Poor 
Control 
 
 
 
 
Good Control 
 
 
 
 
1.4734 
 
 
 
 
.2508 
 
 
 
 
0.0001 
 
 
 
Fair Control 
 
 
 
.8657 
 
 
 
.2124 
 
 
 
0.0001 
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FIGURE 22: COMPARISON OF  MPV AND HbA1C  
 
 
The MPV in the study population was compared with the HbA1C 
values, with ANOVA  demonstrated a relation which was statistically 
significant(p=.000) . 
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TABLE 30:COMPARISON OF MPV AND DURATION OF 
DIABETES  
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TABLE 31:COMPARISON OF MPV AND DURATION OF 
DIABETES STATISTICS 
(I) Duration 
Mean 
Difference (I-
J) Std. Error Sig. 
Upto 1 yr Above 1 to 5 yrs -.3312 .2293 .475 
6 to 10 yrs -1.7984 .2652 .000 
 
Above 10 yrs 
 
-1.2658 
 
.4006 
 
.011 
 
Above 1 to 
5 yrs 
 
Upto 1 yr 
 
.3312 
 
.2293 
 
.475 
 
6 to 10 yrs 
 
-1.4672 
 
.2142 
 
.000 
 
Above 10 yrs 
 
-.9346 
 
.3689 
 
.061 
 
 
6 to 10 yrs 
 
 
Upto 1 yr 
 
 
1.7984 
 
 
.2652 
 
 
.000 
 
 
Above 1 to 5 yrs 
 
 
1.4672 
 
 
.2142 
 
 
.000 
 
 
Above 10 yrs 
 
 
.5326 
 
 
.3922 
 
 
.529 
 
 
Above 10 
yrs 
 
 
Upto 1 yr 
 
 
1.2658 
 
 
.4006 
 
 
.011 
 
 
Above 1 to 5 yrs 
 
 
.9346 
 
 
.3689 
 
 
.061 
 
 
6 to 10 yrs 
 
 
-.5326 
 
 
.3922 
 
 
.529 
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FIGURE 23 :COMPARISON OF MPV AND DURATION OF 
DIABETES 
 
 
 
 
The MPV in the study population was compared with the duration of 
diabetes, with ANOVA  demonstrated a relation which was statistically 
significant(p=.011) . 
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TABLE 32:COMPARISON OF MPV AND DURATION OF 
DIABETES STATISTICS 
 
DURATION N MPV 
Upto 1 yr 
 
Above 1 to 5 yrs 
 
Above 10 yrs 
 
6 to 10 yrs 
19  
 
52  
 
6  
 
23 
7.584 
 
 7.915 
 
8.850 
 
9.383 
 
The variation in MPV values in the study population with regard 
to the duration of diabetes was studied, although the age group size are 
unequal. 
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TABLE 33:COMPARISON OF MPV AND BMI DESCRIPTIVE 
STATISTICS 
 
In the study population MPV in various BMI ranges were analysed but 
the relation was not statistically sinificant with a p value of  0.180. 
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FIGURE 24:COMPARISON OF MPV AND BMI 
 
 
 
The MPV in the study population was compared with the BMI, with 
ANOVA  demonstrated a relation which was not statistically 
significant(p=.180) . 
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TABLE 34: COMPARISON OF MPV AND AGE 
 
The descriptive statistics of the study population showing the mean 
platelet volume in different age groups in the study population. 
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(I) Agerange (J) Agerange Mean 
Difference 
(IJ) 
 
 
Std. 
Error  
Sig. 
Upto 40 yrs 41 to 50 yrs 
51 to 60 yrs 
Above 60 yrs 
-.4416 
-.6500 
-1.2482 
.3245 
.3344 
.3436 
.527 
.217 
003 
41 to 50 yrs Upto 40 yrs 
51 to 60 yrs 
Above 60 yrs 
.4416 
-.2084 
-.8066 
.3245 
.2607 
.2724 
.527 
.855 
.020 
51 to 60 yrs Upto 40 yrs 
41 to 50 yrs 
Above 60 yrs 
.6500 
.2084 
-.5982 
.3344 
.2607 
.2842 
 
.217 
.855 
.159 
Above 60 yrs Upto 40 yrs 
41 to 50 yrs 
51 to 60 yrs 
1.2482 
.8066 
.5982 
.3436 
.2724 
.2842 
.003 
.020 
.159 
 
TABLE 37 : COMPARISON OF MPV AND AGE 
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FIGURE25: COMPARISON OF MPV AND AGE 
 
 
TABLE 38 : COMPARISON OF MPV AND AGE 
AGE RANGE N MPV 
UPTO 40 YRS 14 7.164 
41-50 YRS 34 8.056 
51-60YRS 28 8.264 
ABOVE 60YRS 24 8.863 
 
 
 
 
 
 
 
100 
 
 MPV 
Duration of Diabetes  t value           
P value 
                                   N 
0.521 
0.0001 
100  
 
TABLE 39 : CORRELATION OF MPV AND DURATION OF 
DIABETES 
In conclusion, in the study the duration of diabetes was 
significantly related to the MPV is significant at 0.01 level.Also the 
HbA1C was significantly related to the MPV at 0.01 level of 
significance. 
TABLE 40:CORRELATION OF MPV AND HbA1C 
 MPV 
  HbA1C                     t value 
                                   P value 
                                   N 
0.676 
0.0001 
100 
 
A highly significant correlation was noted between HbA1C and MPV 
with a T value of 0.676 and p value of 0.0001 among the hundred 
patients studied. 
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TABLE41:CORRELATION OF MPV AND DURATION OF 
DIABETES AND HbA1C 
VARIABLE t value P value Inference 
Duration of diabetes 
 
 
 
HbA1C 
 
 
0.521 
 
 
 
0.676 
 
0.0001 
 
 
 
0.0001 
 
 
Highly 
significant 
 
 
Highly 
significant 
 
Finally charting the study in a table, showing the significant relation of 
MPV and durationof diabetes and HbA1C at significance level of 
0.0001. 
In the above table, the result of the study is charted as the correlation 
between the mean platelet volume and duration of diabetes with a t 
value of 0.521 and p value of 0.0001 which is highly significant. Also, 
the relationof glycated hemoglobin and mean platelet volume showed a 
t value 0f 0.676 and a highly significant p value of 0.00001.  
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FIGURE 26: GRAPHICAL REPRESENTATION OF MPV 
DISTRIBUTION WITH DURATION OF DIABETES 
A linear relation with MPV and duration of diabetes was noted in the 
study. 
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FIGURE 26: GRAPHICAL REPRESENTATION OF MPV 
DISTRIBUTION WITH HbA1C 
A linear relation was noted with MPV with increasing HbA1C values. 
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DISCUSSION 
This study conducted at Government Stanley Hospital with an 
aim to identify the effect of glycemic control on mean platelet volume. 
This is cross sectional study aimed at population consulting at medical 
departments and the department of diabetology of Government Stanley 
Hospital. 
Following passages will describe and discuss the study finding 
in comparison with standard data and reviews available for mean 
platelet volume and its relation to glycemic control. 
Previous studies have documented various platelet abnormalities 
especially an increase in mean platelet volume in diabetic subjects. 
The average age of patients enrolled in the study was 52.12 years. In 
the subjects studied majority were in the age group of 41-50 years of 
age, with 34%, and then the age group of 51-60 years with 28% and 
24% in the age group of above 60 years. 14% of the subjects were 
below 40 years of age. 
Out of the 100 patients studied 58 were females and 48 males, 
thus a majority of female subjects were included in this study(58%). 
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In the study by Shah B et al. published in 2012 studied 13021 
subjects of which 1558 were diabetic patients. In the study 48% were 
males with the predominance of females by 52%, similar to the current 
study. The mean age of the population studied was 47 years with 
subjects of age ranging from 21 to 85 years of age. In the study the 
population was divided into 3 groups according to their HbA1C levels 
and it was found that the mean platelet volume in patients with HbA1C 
more than 8 was higher [8.2] when compared to the group with HbA1C 
of less than 6.5 was lower[8.06] with high significance.128 
In the study done by Jabeen F et al.51 diabetic subjects and 55 
controls were studied with an average age of 52 years. 55% of the 
studied population with diabetes were males. The study revealed a 
higher mean platelet volume in subjects with poor glycemic control 
compared to the well-controlled population grouped according to the 
HbA1C values. In the study the male diabetics had an average MPV of 
8.9fL.whereas to female diabetics had an MPV value of 9.53Fl with a 
similar HbA1C values [6.7]. In the current study also a similar picture 
of larger MPV was noted in the female diabetic population but it was 
not statistically significant129. 
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In an Indian study done by Kodiette et al. 255 diabetic patients 
was studied with match controls. 65% of the studied population were 
males with an average age of 55years. The average duration of diabetes 
was 6.5 years, BMI 25,FBS150,PPBS252. 
The study demonstrated as statistically significant increase in 
MPV with rising HbA1C. The main HbA1C in the studied population 
was 9.13Fl. In the group with HbA1C of less than 6.5 showed an 
average MPV of 7.95 whereas in the group with HbA1C value of 6.5 
and more showed an average MPV of 8.35 130. 
Papanas N et al. in 2004 studied 416 subjects with 265 diabetic 
patients with an average age of 67 years. The studied population 
consisted 51% of females and an average of 14 years history of 
diabetes. In the study the diabetic population had 14Fl of MPV 
compared to 7Fl in the non-diabetic population evaluated in the 
study131. 
Zuberi et al studied a total of 600 subjects with 200 diabetic 
patients with the mean age of 40 and found that the mean platelet 
volume increased with increasing glycemic status. 
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In a study done in Mangalore which was similar to the current 
study with 100diabetic patients with 50 controls. The study focused on 
the use of insulin and oral hypoglycemic agents on the mean platelet 
volume in diabetic subjects. The MPV values in the study were similar 
to the current study with the diabetic population on OHAs was around 
8.08 fL and controls with 7.96 Fl of MPV values. The majority of 
population in the current study was on OHAs alone for the treatment of 
diabetes and had a similar MPV values. 
The majority of population in the current study was on oral 
hypoglycemic agents alone for the treatment of diabetes and had a 
similar Mean Platelet Volume values. 
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506 416 1876 612 150 100 
MEN 
WOMEN 
48%: 
52% 
51%: 
49% 
61%: 
39% 
49%: 
51% 
60%: 
40% 
55%: 
45% 
50%: 
50% 
42%: 
58% 
Age,y 
mean+SD 
47 
+/-9.0 
52 
+/- 
7 
55 
+/-  
7 
67.4 
+/- 
9.5 
57.4 
+/- 
10.32 
40 
+/-10.2 
59.5 
+/- 
9.24 
52.12 
+/- 
9.33 
MPV 
(HbA1C)  
8.09 
(<6.5) 
8.24(6.
6-7.9) 
8.35(>
8%) 
 
 
8.38 
+/-
.25(<5.6) 
9.53+/-
.23(>6.5) 
7.95+/-
2.53(<6.5) 
8.35+/- 
.724(>6.5) 
7.1+/-
1.2(ND) 
14.2+/-
2.2(D) 
 
9.97+/-
.69(ND) 
10.12+/-
.79(IGT) 
 
8.63(ND) 
8.98(DC) 
9.34(D-
NC) 
7.96(ND) 
7.53(I) 
8.08(O) 
 
7.29+
/-.786 
(<7) 
7.9+/-
.659(
7.1-8) 
 
8.76+
/-
1.068
(>8) 
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LIMITATIONS OF STUDY 
There are a few limitations to the study that is needed to be mentioned  
1) There were only 100 patients in the study. Sample size was 
small. 
2) The study was confined to a small geographical area. 
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CONCLUSION 
The conclusions of this study are following: 
1) This study has shown an elevation in Mean Platelet Volume in 
patients with increased HbA1C (glycated hemoglobin) values, 
thus indicating poor control of diabetes and, it can be stated that 
an increase in Mean Platelet Volume is directly proportional to 
the numerical value of HbA1C (glycated hemoglobin) and 
inversely related to the control of diabetes. Statistically 
significant association was found with glycated hemoglobin 
(HbA1C) (P-value =.0001) and mean platelet volume. 
2) Statistically significant association was found with duration of 
diabetes(p=.0001) and mean platelet volume. 
3) The study did not find a statistically significant relation between 
Body Mass Index, lipid profile(total cholesterol, High density 
lipoproteins, Triglycerides, Low density lipoproteins) and Mean 
Platelet Volume. 
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PROFORMA 
1.Name2. Age/Sex 
3. Marital Status 
4. Educational Qualification                          5.Occupation 
6. Address                                                       7.Contacct no 
8.Height(cm)                        9.Weight(kg)                             10.BMI 
11. Duration of diabetes                                12. Treatment duration 
13. Past medical history 
14.SHT15. History of thyroid diseases/CAD 
16.Smoking history                                        17. Alcohol history 
LABORATORY FINDINGS 
1.CBCHb        TC     DC     Plt       MPV      PDW 
2. FBS,PPBS3.HbA1C 
4.FLPT.Chol           HDL                     LDL 
5.BLD UREA                                                6.S. CREATININE 
7. TFT                                   T3     T4          TSH 
  
  
  
  
 
  
MASTER CHART 
 
  
 
  
KEYS TO MASTER CHART 
 
 SN            SERIAL NO 
 A               AGE 
 G               GENDER 
 H               HEIGHT 
 W              WEIGHT 
 BMI          BODY MASS INDEX 
 DD           DURATION OF DIABETES 
 RX           TREATMENT 
 O              ORAL HYPOGLYCEMICS ALONE 
 O+I           ORAL HYPOGLYCEMIC AND INSULIN 
 H               HISTORY OF HYPERTENSION 
 S                HISTORY OF SMOKING 
 A                HISTORY OF ALCOHOL 
 BP              BLOOD PRESSURE 
 Hb              HEMOGLOBIN 
 TC              TOTAL COUNT 
 PLT             PLATELET COUNT 
 MV             MEAN PLATELET VOLUME 
 PW              PLATELET DISTRIBUTION WIDTH 
 FB               FASTING BLOOD SUGAR 
 PP               POST PRANDIAL BLOOD SUGAR 
 H1C            GLYCATED HEMOGLOBIN 
 CH              CHOLESTEROL 
 TG               TRIGLYCERIDES 
 LD              LOW DENSITY LIPOPROTIEN 
 HD            HIGH DENSITY LIPOPROTIEN 
 UR             UREA 
 CR             CREATININE 
 T3               T3-Triiodothyronine 
 T4                T4-Thyroxine 
 TH              Thyroid Stimulating Hormone 
 
  
 
 
